Ihc – Breast Cancer Prognosis Profile # 2a (Er, Pr, Her2neu Gene Amplification, Dna Ploidy)

16,000.00

Categories: ,

This test panel combines Immunohistochemistry (IHC) and genetic/cytometric analysis to evaluate key biomarkers and genomic characteristics of breast cancer. The panel includes:

• ER (Estrogen Receptor): Detects if cancer cells are responsive to estrogen, helping predict response to hormonal therapy.
• PR (Progesterone Receptor): Determines if the tumor is influenced by progesterone, also guiding hormonal treatment options.
• HER2neu Gene Amplification: Uses techniques such as FISH (Fluorescence In Situ Hybridization) to assess whether the HER2 gene is over-amplified, which may indicate a more aggressive tumor and suitability for HER2-targeted therapies.
• DNA Ploidy: Analyzes the DNA content of tumor cells to classify them as diploid (normal) or aneuploid (abnormal). Aneuploidy is often associated with high-grade, aggressive tumors and a worse prognosis.

This panel provides a detailed molecular and genetic profile to aid in breast cancer classification and treatment planning.

Description

Why It’s Done:

This test is conducted to:
• Determine hormone receptor status (ER/PR) for the selection of hormonal therapy.
• Assess HER2 gene amplification, guiding the use of HER2-targeted treatments such as trastuzumab or pertuzumab.
• Evaluate DNA ploidy, which helps estimate tumor aggressiveness and potential treatment resistance.
• Assist in prognosis and personalized treatment decisions by combining receptor status with genetic indicators of tumor behavior.
This comprehensive profile supports a more tailored approach to breast cancer care.

Preparation:

• No special patient preparation is required for this test.
• The test is performed on formalin-fixed tissue samples obtained during a biopsy or surgical excision.
• If undergoing biopsy or surgery, your doctor may advise specific instructions such as:
o Fasting (in some surgical procedures)
o Pausing certain medications
o Arranging for someone to accompany you home
Always follow your healthcare provider’s guidance